Professor Bickle obtained his PhD at the Biozentrum of the University of Basel, Switzerland, before moving to Cambridge, UK and later Lyon, France, where he was involved in the creation of a biotech company. Currently, he heads the screening facility of the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBG) in Dresden, Germany, where he is developing chemical genomic cellular assays using automated microscopy, image analysis and multivariate statistics. He brings extensive technological experience to Cellectricon’s Advisory board, and will specifically support work with live cell high content screening, as well as data and image analysis.
Professor Svensson obtained her PhD at UC San Diego, where she also held a postdoctoral research position at the Department of Medicine. She subsequently moved on to Karolinska Institute, Stockholm, Sweden, where she today holds a position as Professor in Cellular and Molecular Pain Physiology and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology. Her research is focused on investigating the role of neuroinflammation in the peripheral and the central nervous system, with particular focus on pain mechanisms in conditions with joint inflammation and autoimmunity, such as rheumatoid arthritis. Professor Svensson brings vast disease area knowledge to the Advisory board and will be a key contributor in shaping Cellectricon’s chronic pain R&D strategy.
Dr. Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and at University College London, UK, as well as the Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden. With a background in molecular biology and medicine, Dr. Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has published more than 900 scientific articles and has received the Erik K. Fernström prize for young scientists, the Inga Sandeborg prize for research on Alzheimer’s disease and the Parkinson Research Foundation Research Award. Professor Zetterberg brings extensive expertise in neurodegenerative diseases to the Advisory board, and he will be a key contributor in further enhancing Cellectricon’s CNS discovery services.
Annika Malmberg is a neurobiology and pharmacology expert with 20 years of experience in drug discovery and development working at companies ranging in size from small start-up companies to large biotech and pharmaceutical companies, including Amgen, Roche Biosciences, Élan Pharmaceuticals, NeurogesX and Quartet Medicine. Currently, Dr. Malmberg is an independent pharmacology/neurobiology consultant based in Cambridge, MA. Dr. Malmberg received her PhD in Pharmacology and Physiology from University of Gothenburg, Sweden, and a MSc in Pharmacy from University of Uppsala, Sweden. She also performed pre-and postdoctoral studies with Dr. Tony Yaksh and Dr. Allan Basbaum at UCSD and UCSF, respectively. Scientific accomplishments include authorship of over 50 refereed scientific journal articles, book chapters, editorial service and the reception of the John C. Liebeskind Early Career Scholar Award, the American Pain Society. With considerable expertise in industrial drug discovery, Dr. Malmberg will play an important role in supporting Cellectricon’s commercial strategy development.
Dr. Nieland obtained his PhD at the VU University of Amsterdam and currently holds the position of Research Associate Professor at the Biomedical Engineering Department of Tufts University in Boston, MA. He also shares leadership of the Initiative of Neural Science, Disease and Engineering at Tufts University (INSciDE@Tufts). This is an interdisciplinary research center with the mission to accelerate the discovery of therapeutic solutions to brain disease, integrating technological innovations in biomedical engineering with stem cell biology and regenerative medicine. Dr. Nieland brings extensive expertise in neurodegenerative disease, neuropsychiatry and stem cell research to the Advisory board, and he will be a key contributor in further enhancing Cellectricon’s CNS disease research. At Tufts University, Dr. Nieland’s research is focused on human brain disease, in particular on identifying disease mechanisms, targets and drugs to treat autism spectrum disorders, Parkinson’s and Alzheimer’s disease. Previously, Dr. Nieland performed research at Harvard University, MIT, the Broad Institute of Harvard and MIT, Johns Hopkins University, Stanford University and Merck Research Laboratories.